skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients

Review

(2953) Views  (663) Full article downloads

Authors: Per Pfeiffer, Camilla Qvortrup, Jon K Bjerregaard

Published Date December 2008 Volume 2009:2 Pages 17 - 27
DOI: http://dx.doi.org/10.2147/OTT.S3651

Per Pfeiffer, Camilla Qvortrup, Jon K Bjerregaard

Department of Oncology, Odense University Hospital. Institute of Clinical Research, University of Southern Denmark. Odense C, Denmark

Purpose: Elderly cancer patients often have co-morbidities and other characteristics that make the selection of optimal treatment more complex. The introduction of targeted therapies in colorectal cancer has further complicated this problem. This review will focus on the role of the EGFR antibody cetuximab in elderly patients.

Methods: We have reviewed the available evidence in the literature to evaluate the results of therapy with cetuximab, alone or in combination with chemotherapy, with a focus on elderly patients with metastatic colorectal cancer (mCRC).

Results: In patients with mCRC, combination chemotherapy prolongs median survival to more than 18 months and even around 24 months in combination with cetuximab in selected patients. No prospective studies have evaluated cetuximab in elderly patients. However, subgroup analyses from randomized trials and retrospective analysis suggest that the efficacy of chemotherapy and cetuximab is maintained in fit elderly patients, but with slightly increased but acceptable toxicity.

Conclusion: No prospective cetuximab studies have been conducted solely in a population of elderly patients. However, available data suggest that outcomes in the fit elderly mirror results observed in younger patients.

Keywords: metastatic colorectal cancer, cetuximab, elderly patients








Readers of this article also read:

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
Targeted therapies in the management of colorectal carcinoma: role of bevacizumab
First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
Rational use of cetuximab in the treatment of advanced non-small cell lung cancer
Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)